๐Ÿ”ฅ๐Ÿ” BizChicken ๐Ÿ”๐Ÿ”ฅ

Companies Similar to Spero Therapeutics, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Biogen Inc.

Biogen Inc. logo
Market Cap: Highest
Employees: Highest

TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS

Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.

Tags: biotechnology, multiple sclerosis, neurodegenerative diseases, neurological diseases, pharmaceuticals

Symbol: BIIB

Recent Price: $150.19

Industry: Drug Manufacturers - General

CEO: Mr. Christopher A. Viehbacher

Sector: Healthcare

Employees: 7570

Address: 225 Binney Street, Cambridge, MA 02142

Phone: 617 679 2000

Leadership

  • Christopher A. Viehbacher, President and Chief Executive Officer
  • Susan H. Alexander, Chief Legal Officer
  • Ginger Gregory, Ph.D., Chief Human Resources Officer
  • Jane Grogan, Ph.D., Head of Research
  • Rachid Izzar, Head of Global Product Strategy & Commercialization
  • Adam Keeney, Head of Corporate Development
  • Michael McDonnell, Chief Financial Officer
  • Nicole Murphy, Head of Pharmaceutical Operations and Technology
  • Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
  • Alisha Alaimo, President, Head of North America
  • Stephen Amato, Head of Investor Relations
  • Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
  • Fraser Hall, President, Head of Intercontinental Region
  • Wolfram Schmidt, President, Head of Europe
  • Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
  • Caroline Dorsa, Chair of the Board
  • Maria C. Freire, Ph.D., Director
  • William A. Hawkins, Director
  • Susan Langer, Director
  • Jesus B. Mantas, Director
  • Lloyd B. Minor, M.D., Director
  • Monish Patolawala, Director
  • Eric K. Rowinsky, M.D., Director
  • Stephen A. Sherwin, M.D., Director

Last updated: 2024-12-31

Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. logo
Market Cap: Low
Employees: Low

Therapeutic Candidates (INBRX-109, INBRX-106)

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops biologic therapeutics for life-threatening conditions, with therapeutic candidates in phase 2 clinical trials targeting various cancers.

Tags: biologic therapeutics, biopharmaceutical, cancer treatment, clinical-stage

Symbol: INBX

Recent Price: $15.14

Industry: Biotechnology

CEO: Mr. Mark Paul Lappe

Sector: Healthcare

Employees: 166

Address: 11025 North Torrey Pines Road, La Jolla, CA 92037

Phone: 858-795-4220

Last updated: 2024-12-31

Spero Therapeutics, Inc.

Spero Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Tebipenem pivoxil hydrobromide (HBr), SPR206, SPR720

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for multi-drug resistant bacterial infections and rare diseases in the United States.

Tags: MDR infections, antibiotics, biopharmaceutical, clinical-stage, healthcare, rare diseases

Symbol: SPRO

Recent Price: $1.02

Industry: Biotechnology

CEO: Mr. Satyavrat Shukla C.F.A.

Sector: Healthcare

Employees: 46

Address: 675 Massachusetts Avenue, Cambridge, MA 02139

Phone: 857 242 1600

Leadership

  • Sath Shukla, President and Chief Executive Officer
  • Esther Rajavelu, Chief Financial Officer and Chief Business Officer
  • Timothy Keutzer, Chief Operating Officer
  • James P. Brady, Chief Human Resource Officer
  • Ankit Mahadevia, MD, Chairperson
  • Cynthia Smith, Compensation Committee Chair
  • Frank E. Thomas, Audit Committee Chair
  • Patrick Vink, MD, Nominating and Corporate Governance Chair
  • Milind Deshpande, PhD, Nominating and Corporate Governance Committee Member, Audit Committee Member, and Development Committee Member
  • Scott Jackson, Nominating and Corporate Governance Member and Audit Committee Member
  • John C. Pottage, Jr., M.D., Development Committee Chair
  • Kathleen Tregoning, Compensation Committee Member

Last updated: 2024-12-31

Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. logo
Market Cap: High
Employees: Lowest

antibody therapeutics

Spyre Therapeutics, Inc. is a biotechnology company focusing on antibody therapeutics for treating inflammatory bowel disease, using advanced engineering and precision medicine.

Tags: antibody therapeutics, biotechnology, inflammatory bowel disease, precision medicine

Symbol: SYRE

Recent Price: $22.54

Industry: Biotechnology

CEO: Dr. Cameron Turtle DPHIL, Ph.D.

Sector: Healthcare

Employees: 50

Address: 221 Crescent Street, Waltham, MA 02453

Phone: 617 651 5940

Last updated: 2024-12-31

Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. logo
Market Cap: Highest
Employees: Medium

EXONDYS 51, VYONDYS 53, AMONDYS 45, SRP-5051, SRP-9001, SRP-9003

Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA-targeted therapeutics and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy.

Tags: Duchenne muscular dystrophy, RNA-targeted therapeutics, biopharmaceutical, gene therapy, rare diseases

Symbol: SRPT

Recent Price: $121.19

Industry: Biotechnology

CEO: Mr. Douglas S. Ingram Esq.

Sector: Healthcare

Employees: 1314

Address: 215 First Street, Cambridge, MA 02142

Phone: 617 274 4000

Leadership

  • Douglas S. Ingram, President and Chief Executive Officer
  • Bilal Arif, Executive Vice President, Chief Technical Operations Officer
  • Diane Berry, PhD, Executive Vice President, Chief Global Policy & Advocacy Officer
  • Ryan E. Brown, JD, Executive Vice President, Chief General Counsel
  • Ian M. Estepan, Executive Vice President, Chief Financial Officer
  • Dallan Murray, Executive Vice President, Chief Customer Officer
  • Alison Nasisi, Executive Vice President, Chief People Officer
  • Louise R. Rodino-Klapac, PhD, Executive Vice President, Head of R&D, Chief Scientific Officer
  • Will Tilton, Senior Vice President, Head of Strategy, Chief of Staff
  • M. Kathleen Behrens, PhD, Chairwoman
  • Richard J. Barry,
  • Kathryn Boor, PhD,
  • Michael Chambers,
  • Deirdre Connelly,
  • Stephen L. Mayo, PhD,
  • Claude Nicaise, MD,
  • Hans Wigzell, MD, PhD,
  • John C. Martin, PhD (In Memoriam),
  • Annemieke Aartsma-Rus, PhD,
  • Carsten Bรถnnemann, MD,
  • Joy Cavagnaro, PhD, DABT, Fellow ATS,
  • Kay Davies, PhD, DBE FMedSci FRS,
  • Steven Gray, PhD,
  • Angela J. Russell, DPhil,

Last updated: 2024-12-31

Travere Therapeutics, Inc.

Travere Therapeutics, Inc. logo
Market Cap: Medium
Employees: Medium

Chenodal, Cholbam, Thiola, Sparsentan, TVT-058

Travere Therapeutics, Inc. is a biopharmaceutical company that focuses on identifying, developing, commercializing, and delivering therapies for the treatment of rare diseases. Its products include Chenodal, Cholbam, Thiola, and candidates like Sparsentan and TVT-058.

Tags: Chenodal, Cholbam, Sparsentan, TVT-058, Thiola, biopharmaceutical, rare diseases, therapeutics

Symbol: TVTX

Recent Price: $17.32

Industry: Biotechnology

CEO: Dr. Eric M. Dube Ph.D.

Sector: Healthcare

Employees: 380

Address: 3611 Valley Centre Drive, San Diego, CA 92130

Phone: 888 969 7879

Leadership

  • Eric Dube, Ph.D., President & Chief Executive Officer
  • Chris Cline, CFA, Chief Financial Officer
  • Angela Giannantonio, Senior Vice President, Human Resources
  • Peter Heerma, Chief Commercial Officer
  • Jula Inrig, M.D., Chief Medical Officer
  • Casey Logan, Chief Business Officer
  • Elizabeth Reed, J.D., Senior Vice President, General Counsel, Corporate Secretary
  • William Rote, Ph.D., Senior Vice President, Research & Development
  • Charlotte Smith, Senior Vice President, Public Affairs
  • Gary A. Lyons, Chairman
  • Roy D. Baynes, M.D., Ph.D.,
  • Suzanne L. Bruhn, Ph.D.,
  • Tim Coughlin, CPA,
  • Jeffrey A. Meckler,
  • John A. Orwin,
  • Sandra E. Poole,
  • Ron Squarer,
  • Ruth Williams-Brinkley, FACHE,

Last updated: 2024-12-31

Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

Sympazan, Suboxone, Zuplenz, Azstarys, Libervant, Exservan

Aquestive Therapeutics, Inc. is a pharmaceutical company committed to identifying, developing, and commercializing innovative products to address unmet medical needs, both in the U.S. and globally. It specializes in oral soluble film formulations for various treatments, including neurological conditions and opioid dependence.

Tags: ADHD, ALS, biotechnology, neurology, opioid dependence, oral soluble film, pharmaceutical

Symbol: AQST

Recent Price: $3.52

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Daniel Barber

Sector: Healthcare

Employees: 135

Address: 30 Technology Drive, Warren, NJ 07059

Phone: 908 941 1900

Last updated: 2024-12-31

BeiGene, Ltd.

BeiGene, Ltd. logo
Market Cap: Highest
Employees: Highest

BRUKINSA, Tislelizumab, REVLIMID, VIDAZA, XGEVA, BLINCYTO, KYPROLIS, SYLVANT, QARZIBA, Pamiparib, Pobevcy

Bei Gene, Ltd. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing a wide range of medicines globally, specializing in oncology treatments and clinical stage drug candidates.

Tags: Biotechnology, Medicines, Oncology, Pharmaceuticals, Research and Development

Symbol: BGNE

Recent Price: $183.81

Industry: Biotechnology

CEO: Mr. John V. Oyler

Sector: Healthcare

Employees: 10000

Address: 55 Cambridge Parkway, Cambridge, MA 02142

Phone: 781-801-1800

Leadership

  • John V. Oyler, Co-Founder, Chairman and CEO
  • Xiaodong Wang, Ph.D., Co-Founder, Chairman of Scientific Advisory Board
  • Olivier Brandicourt, M.D., Director
  • Margaret Dugan, M.D., Director
  • Donald W. Glazer, Director
  • Michael Goller, Director
  • Anthony Hooper, Director
  • Ranjeev Krishana, Director
  • Michael Nuoqing Yi, Director
  • Alessandro Riva, M.D., Director
  • Corsee Sanders, Ph.D., Director
  • Shalini Sharp, Director
  • Steven Young, Ph.D., Acting Head of Medicinal Chemistry
  • Ron Levy, M.D., Scientific Advisory Board
  • Neal Rosen, M.D., Ph.D., Scientific Advisory Board
  • Charles Sawyers, M.D., Scientific Advisory Board
  • David Schenkein, M.D., Scientific Advisory Board
  • Melika Davis, SVP & Global Head, Clinical Operations
  • Clare Fisher, SVP, Business Development, Licensing, and M&A (ex-China)
  • Tony Guo, Ph.D., SVP, Global Statistics & Data Science
  • Dany Habr, M.D., Head of Medical Affairs, North America & International Markets
  • Graham Hardiman, Global Head of HR
  • Shreya Devendra Jani, SVP, Corporate Affairs
  • Jaspreet Jaggi, M.D., Ph.D., SVP and Head, Clinical Portfolio Strategy
  • Yang Ji, Chief Compliance Officer
  • Mark Lanasa, M.D., Ph.D., SVP, Chief Medical Officer, Solid Tumors
  • Chan Lee, General Counsel
  • Kyu-Sung Lee, Ph.D., SVP, Global Head of Technical Operations and Manufacturing
  • Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer
  • Kyoung Lim, VP of Supply Chain
  • Han Ma, M.D., Ph.D., Chief Safety Officer and SVP, Global Patient Safety
  • Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology
  • Richard Oโ€™Keeffe, Head of Global Quality
  • Jurij Petrin, M.D., Head of New Market Development
  • Yan Qi, Ph.D., SVP, Head of Public Affairs
  • Hongyu Qian, SVP, Medical Affairs
  • Jason Radford, SVP, Strategy & Corporate Development
  • Anand Reddi, VP, Global Strategic Initiatives and Corporate Operations, Chief of Staff to the CEO
  • Adam Roach, VP and Head of Asia Pacific
  • Aaron Rosenberg, Chief Financial Officer
  • Michael Schoen, Strategic Advisor and Special Assistant to the CEO
  • Matt Shaulis, General Manager of North America
  • Lai Wang, Ph.D., Global Head of R&D
  • Zhiwei Wang, Ph.D., SVP, Research Head of Chemistry
  • Beth Wensley, SVP, Head of Portfolio and Program Management
  • Kimberly Wolf, SVP, Global Commercial Strategy & Operations
  • Xiaobin Wu, Ph.D., President, Chief Operating Officer
  • Eva Yin, Chief Commercial Officer, Greater China

Last updated: 2024-12-31

Chimerix, Inc.

Chimerix, Inc. logo
Market Cap: Low
Employees: Low

TEMBEXA (brincidofovir)

Chimerix, Inc. is a biopharmaceutical company that develops medicines to enhance the lives of patients with serious diseases, including smallpox and various tumors.

Tags: biopharmaceutical, clinical trials, medicine development, smallpox, tumors

Symbol: CMRX

Recent Price: $3.44

Industry: Biotechnology

CEO: Mr. Michael T. Andriole M.B.A.

Sector: Healthcare

Employees: 72

Address: 2505 Meridian Parkway, Durham, NC 27713

Phone: 919 806 1074

Leadership

  • Mike Andriole, President, CEO
  • Joshua E. Allen, PhD, Chief Scientific Officer
  • Michael A. Alrutz, JD, PhD, Senior Vice President and General Counsel
  • Michelle LaSpaluto, Chief Financial Officer
  • Allen Melemed, MD, MBA, Chief Medical Officer
  • Tom Riga, Chief Operating and Commercial Officer
  • Roy W. Ware, PhD, MBA, Chief Manufacturing Technology Officer
  • Caryn Barnett, Vice President Clinical Operations
  • Tom Brundage, Vice President Biostatistics
  • David Jakeman, VP Accounting and Finance
  • Christopher Jordan, Vice President Regulatory Affairs
  • Pablo Lee, Vice President Medical Affairs
  • Odin Naderer, PharmD, Vice President Clinical Pharmacology and Translational Medicine
  • Mike Sherman, Chairman
  • Martha J. Demski, Lead Independent Director
  • Lisa Decker, PhD,
  • Marc D. Kozin,
  • Robert J. Meyer, MD,
  • Fred A. Middleton,
  • Pratik S. Multani, MD,
  • Vicki Vakiener,

Last updated: 2024-12-31

Structure Therapeutics Inc.

Structure Therapeutics Inc. logo
Market Cap: High
Employees: Low

GSBR-1290

Structure Therapeutics Inc. develops novel oral therapeutics for chronic diseases with unmet medical needs, focusing on conditions like type-2 diabetes, obesity, pulmonary, and cardiovascular diseases.

Tags: GPCR, biopharmaceutical, cardiovascular diseases, chronic diseases, obesity, oral therapeutics, pulmonary diseases, type-2 diabetes

Symbol: GPCR

Recent Price: $26.63

Industry: Biotechnology

CEO: Dr. Raymond C. Stevens Ph.D.

Sector: Healthcare

Employees: 136

Address: 611 Gateway Boulevard, South San Francisco, CA 94080

Phone: 628-229-9277

Last updated: 2024-12-31

Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc. logo
Market Cap: Medium
Employees: Lowest

SEL-302, SEL-212

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for treating and preventing human diseases. The company has various programs including gene therapies and biologic therapies for conditions like methylmalonic acidemia and chronic refractory gout.

Tags: autoimmune diseases, biologic therapies, biopharmaceutical, gene therapy, nanoparticle drugs

Symbol: RNAC

Recent Price: $18.76

Industry: Biotechnology

CEO: Dr. Carsten Brunn Ph.D.

Sector: Healthcare

Employees: 37

Address: 65 Grove Street, Watertown, MA 02472

Phone: 617 923 1400

Last updated: 2024-12-31

Scopus BioPharma Inc.

Scopus BioPharma Inc. logo
Market Cap: Lowest
Employees: Lowest

Duet Platform

Scopus Bio Pharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics for serious diseases with lead programs in immuno-oncology gene therapy.

Tags: biopharmaceutical, cancer treatment, gene therapy, immuno-oncology, therapeutics

Symbol: SCPS

Recent Price: $0.00

Industry: Biotechnology

CEO: Dr. Alan D. Horsager Ph.D.

Sector: Healthcare

Employees: 13

Address: 420 Lexington Avenue, New York, NY 10170

Phone: 212 479 2513

Last updated: 2024-12-31

Silo Pharma, Inc.

Silo Pharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

SPC-15

Silo Pharma Inc. is a developmental stage biopharmaceutical company focusing on treatments for stress-induced psychiatric disorders, chronic pain, and CNS diseases through traditional and psychedelic therapies.

Tags: CNS diseases, biopharmaceutical, chronic pain, psychedelic treatments, psychiatric disorders, traditional therapies

Symbol: SILO

Recent Price: $0.89

Industry: Biotechnology

CEO: Mr. Eric Weisblum

Sector: Healthcare

Employees: 3

Address: 677 N. Washington Boulevard, Sarasota, FL 34236

Phone: 718 400 9031

Last updated: 2024-12-31

Soligenix, Inc.

Soligenix, Inc. logo
Market Cap: Lowest
Employees: Lowest

SGX301 (Hy Bryte), SGX942, SGX203, SGX302

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, operating in the Specialized Bio Therapeutics and Public Health Solutions segments.

Tags: Crohn's disease, SGX301, SGX942, biopharmaceutical, oral mucositis, psoriasis, rare diseases

Symbol: SNGX

Recent Price: $2.91

Industry: Biotechnology

CEO: Dr. Christopher J. Schaber Ph.D.

Sector: Healthcare

Employees: 13

Address: 29 Emmons Drive, Princeton, NJ 08540

Phone: 609 538 8200

Leadership

  • Christopher J. Schaber, PhD, Chairman, President and Chief Executive Officer
  • Gregg A. Lapointe, CPA, MBA, Board Director
  • Diane L. Parks, MBA, Board Director
  • Robert J. Rubin, MD, Board Director
  • Jerome Zeldis, MD, PhD, Board Director

Last updated: 2024-12-31

Tempest Therapeutics, Inc.

Tempest Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

TPST-1495, TPST-1120, TREX-1

Tempest Therapeutics Inc. is a clinical-stage oncology company developing small molecule therapeutics to treat cancer, with key programs in TPST-1495 and TPST-1120, and research in TREX-1 enzyme modulation.

Tags: biotechnology, cancer treatment, clinical-stage, drug development, immune response, oncology, small molecule therapeutics

Symbol: TPST

Recent Price: $0.84

Industry: Biotechnology

CEO: Mr. Stephen R. Brady J.D., LLM

Sector: Healthcare

Employees: 17

Address: 7000 Shoreline Court, South San Francisco, CA 94080

Phone: 415 798 8589

Last updated: 2024-12-31

Vir Biotechnology, Inc.

Vir Biotechnology, Inc. logo
Market Cap: Medium
Employees: Medium

Sotrovimab (VIR-7832), VIR-2218, VIR-3434, VIR-2482, VIR-1111

Vir Biotechnology, Inc. is a commercial-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases, including COVID-19, hepatitis B, influenza A, and HIV.

Tags: COVID-19, HIV, biotechnology, hepatitis B, immunology, infectious diseases, influenza, therapeutics

Symbol: VIR

Recent Price: $7.33

Industry: Biotechnology

CEO: Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.

Sector: Healthcare

Employees: 587

Address: 499 Illinois Street, San Francisco, CA 94158

Phone: 415 906 4324

Leadership

  • Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer and Director
  • Jeff Calcagno, M.D., Executive Vice President and Chief Business Officer
  • Vanina de Verneuil, J.D., Executive Vice President, General Counsel and Corporate Secretary
  • Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head Oncology
  • Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer
  • Jenny Gumm, Ed.D., MBA, Executive Vice President, Chief Human Resources Officer
  • Aine Hanly, Ph.D., Executive Vice President and Chief Technology Officer
  • Jason Oโ€™Byrne, MBA, Executive Vice President and Chief Financial Officer
  • Jennifer Eileen Towne, Ph.D., Executive Vice President and Chief Scientific Officer
  • Arran Attridge, Senior Vice President Corporate Communications
  • Antonio Lanzavecchia, M.D., Senior Vice President and Senior Research Fellow
  • Amalio Telenti, M.D, Ph.D., Executive Vice President and Senior Research Fellow

Last updated: 2024-12-31

Verastem, Inc.

Verastem, Inc. logo
Market Cap: Low
Employees: Low

VS-6766

Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing drugs for cancer treatment, with products such as VS-6766 and trials like RAMP 201 and 202 targeting various cancer types.

Tags: MEK, RAF, RAMP 201, RAMP 202, VS-6766, biopharmaceutical, cancer treatment, drug development

Symbol: VSTM

Recent Price: $3.67

Industry: Biotechnology

CEO: Mr. Daniel W. Paterson

Sector: Healthcare

Employees: 73

Address: 117 Kendrick Street, Needham, MA 02494

Phone: 781 292 4200

Last updated: 2024-12-31

BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. logo
Market Cap: High
Employees: Medium

AG10, BBP-265, BBP-831, BBP-631, Encaleret

Bridge Bio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases, with a pipeline of 30 programs including candidates like AG10, BBP-265, and others in various stages of clinical trials.

Tags: biopharmaceuticals, clinical trials, drug development, genetic diseases

Symbol: BBIO

Recent Price: $27.32

Industry: Biotechnology

CEO: Dr. Neil Kumar Ph.D.

Sector: Healthcare

Employees: 550

Address: 421 Kipling Street, Palo Alto, CA 94301

Phone: 650 391 9740

Last updated: 2024-12-31

Panbela Therapeutics, Inc.

Panbela Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

SBP-101

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for treating various cancers, including pancreatic and ovarian cancers. Its lead product, SBP-101, is undergoing clinical trials for pancreatic cancer treatment.

Tags: biopharmaceutical, cancer treatment, clinical trials, pancreatic cancer, therapeutics

Symbol: PBLA

Recent Price: $0.32

Industry: Biotechnology

CEO: Dr. Jennifer K. Simpson CRNP, M.S.N., Ph.D.

Sector: Healthcare

Employees: 7

Address: 712 Vista Boulevard, Waconia, MN 55387

Phone: 952 479 1196

Leadership

  • Michael T. Cullen, MD, MBA, Chairman, President and Chief Executive Officer
  • Jennifer K Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer
  • Art Fratamico, MBA, Chief Business Officer
  • Dan Donovan, CEO of rareLife Solutions, Inc.
  • Jeff Mathiesen, Director and Audit Committee Chair
  • Jeffrey Jacob, CEO at Cancer Prevention Pharmaceuticals, Inc.
  • Robert Schemel, Director
  • David Harle, Ph.D., Executive with over 25 years of pharmaceutical experience
  • Mr. Donovan, CEO of rareLife Solutions, Inc.

Last updated: 2024-12-31

SCYNEXIS, Inc.

SCYNEXIS, Inc. logo
Market Cap: Lowest
Employees: Lowest

BREXAFEMME (ibrexafungerp tablets)

SCYNEXIS, Inc. is a biotechnology company focused on developing products for the treatment of fungal infections. They offer BREXAFEMME for the treatment of vulvovaginal candidiasis and are developing Ibrexafungerp, an oral and intravenous drug for various fungal infections.

Tags: BREXAFEMME, Biotechnology, Fungal Infections, Ibrexafungerp, Pharmaceuticals

Symbol: SCYX

Recent Price: $1.07

Industry: Drug Manufacturers - Specialty & Generic

CEO: Dr. David Gonzalez Angulo M.D.

Sector: Healthcare

Employees: 29

Address: 1 Evertrust Plaza, Jersey City, NJ 07302-6548

Phone: 201 884 5485

Leadership

  • Armando Anido, Director
  • Steven C. Gilman, Ph.D., Director
  • David Angulo, M.D., President and Chief Executive Officer
  • Scott Sukenick, Chief Legal Officer
  • Ivor Macleod, MBA, CPA, Chief Financial Officer
  • Daniella Gigante, Vice President, Human Resources and Information Technology
  • Rossana Ferrara-Pontoriero, Ph.D., Vice President, Business Development and Alliance Management
  • Guy Macdonald, Chairman of the Board
  • Ann F. Hanham, Ph.D., Director
  • David Hastings, Director
  • Philippe Tinmouth, Director

Last updated: 2024-12-31